Timing Is Everything: From Static to Dynamic Risk Prediction in Cardiogenic Shock

Contemporary risk scores for cardiogenic shock (CS) may retain statistical accuracy yet still fall short in practice when prediction becomes available only after the most actionable window has narrowed. In a syndrome marked by rapid physiological deterioration and high mortality, timing may be as important as discrimination in determining clinical usefulness.In this issue, Holle et al. 1 provide the first prospective external validation of the ORBI risk score in a contemporary cohort of 2,713 patients with ST-segment elevation myocardial infarction without shock at admission. ORBI retained strong discrimination for in-hospital CS (AUC 0.89) and post-procedural CS (AUC 0.87), while also categorizing significant clinical risk gradients across the original ORBI categories. Aside from its statistical results, the study is notable for its prospective design, current cohort, and thorough evaluation of the timing of CS development – an aspect often neglected in previous validations. Yet the most important contribution of this work is not simply that ORBI performs well statistically, but that it highlights a central challenge in shock prediction: the clinical utility of a risk score may vary according to the moment at which it becomes available (Fig. 1).This limitation stems from the score itself. ORBI incorporates variables such as post-PCI TIMI flow that only become available during or after the procedure, creating an inherent temporal mismatch between prediction and prevention 2. In the present study, 68% of patients who developed in-hospital CS did so peri-procedurally. By the time the full score was accessible, a substantial proportion of clinically relevant CS deterioration had already manifested. This observation is clinically relevant as it suggests that a substantial proportion of hemodynamic collapse occurs during a period when decision-making is still developing, but before complete risk information is available. More importantly, when the analysis was restricted to patients not already in shock after leaving the catheterization laboratory, ORBI substantially overestimated absolute CS risk, and its apparent clinical benefit was largely limited to lower decision thresholds 1.Importantly, the limitation is not solely temporal. In the post-procedural setting, ORBI also showed miscalibration, substantially overestimating absolute CS risk, underscoring the challenges of transferring risk models across clinical contexts. These findings highlight that even well-performing models require recalibration before being used to guide clinical decisions in new populations or at different stages of care 1. Interpretation should also account for the more restrictive definition of CS used in this validation cohort, which required evidence of impaired cardiac function in addition to hypotension and hypoperfusion, and might have contributed to differences in observed event rates, further emphasizing how outcome definitions can influence model performance and calibration 2, 3.Even alternative models like SEX-SHOCK can improve discrimination, but they tend to be static and thus do not fully overcome the temporal limitation noted in this validation 3. This distinction has practical importance. An effective risk score should detect risk early enough to guide surveillance, triage, or treatment decisions before overt CS occurs. The study by Holle et al. 1 supports a shift toward phase-specific risk assessment, ideally starting at first medical contact rather than after procedural factors are known. Strategies that aim to stratify risk earlier, before entering the catheterization lab, may better align with the biology and timing of CS, as shown by emerging models such as STOPSHOCK 4.Such early identification opens the possibility of pre-emptive strategies, including intensified monitoring and earlier therapeutic consideration, aimed at preventing CS progression (Fig. 1). This timing dilemma also complicates the design of preventive trials. In DOBERMANN-D and -T 5, 6, elevated ORBI scores helped identify patients considered at increased risk despite the absence of overt shock. Even in those conditions, a large proportion of CS events happened before therapy could start. This highlights that the issue is not failed risk stratification but that the disease may progress more rapidly than the available therapeutic window.The importance of timing extends beyond prediction and into intervention. Trials such as STEMI Door-to-Unload 7 show that a strategy based on sound mechanisms may yield neutral results when applied too early, before the biological target is reached. While ventricular unloading with a microaxial flow pump before PCI seemed physiologically promising, it did not lead to clinical benefits and was associated with higher complications. Conversely, the DanGer Shock trial 8 supports the idea that in established CS, early microaxial flow pump use can lower 180-day mortality, despite more vascular complications. This evidence indicates that timing and hemodynamic context are key determinants of intervention effectiveness. What may be ineffective early in STEMI might be beneficial once low-output, hypotensive shock develops. Similarly, ORBI appears more useful for post-procedural risk assessment than for detecting the earliest signs of CS, though it would need recalibration to guide post-PCI decisions.Collectively, these observations support a central idea: CS is not simply an on/off condition but a fluctuating spectrum. Risk levels change, physiology worsens, and treatment success heavily depends on timing. While static scores can be helpful, their usefulness depends on matching them to the care stage when their data are accessible. The ideal predictive framework would, therefore, not replace existing tools but integrate them into a dynamic strategy in which risk is reassessed across successive clinical stages (Fig. 1).Future approaches should move beyond a one-time, late procedural estimate toward phase-specific systems that combine early and serial information, allowing risk to be updated as the patient evolves. This prospective validation demonstrates that ORBI clarifies the phase of care in which its application may be most relevant. In CS prediction, the challenge is not only to identify who is at risk, but to do so at a stage when action remains possible. In that sense, timing is not a secondary property of prediction; it is the condition that ultimately defines its clinical utility.The authors have no conflicts of interest to declare.This study was not supported by any sponsor or funder.J.A.O.H. conceived the manuscript, developed its conceptual framework, and drafted the initial version. G.R.C. contributed to the conceptual development of the manuscript and the design of the central illustration. Both authors approved the final version for submission.